Ranjana Advani

Publications

• Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH. J Clin Oncol. 2013; 31 (1): 88-94
• Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ. Ann Oncol. 2013; 24 (4): 1044-8
• Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. Koontz MZ, Horning SJ, Balise R, Greenberg PL, Rosenberg SA, Hoppe RT, Advani RH. J Clin Oncol. 2013; 31 (5): 592-8
• Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD. J Clin Oncol. 2013; 31 (6): 692-700
• Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. J Clin Oncol. 2013; 31 (6): 684-91
• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. J Clin Oncol. 2012; 30 (18): 2190-6
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Advani RH, Hong F, Horning SJ, Kahl BS, Manola J, Swinnen LJ, Habermann TM, Ganjoo K. Leuk Lymphoma. 2012; 53 (4): 718-20
• In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R. Blood. 2012; 119 (2): 355-63
• Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, Advani R, Hong F, Horning SJ. J Clin Oncol. 2012; 30 (25): 3119-26
• Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. PLoS One. 2012; 7 (5): e33788
• CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Burington B, Yue P, Shi X, Advani R, Lau JT, Tan J, Stinson S, Stinson J, Januario T, de Vos S, Ansell S, Forero-Torres A, Fedorowicz G, Yang TT, Elkins K, Du C, Mohan S, Yu N, Modrusan Z, Seshagiri S, Yu SF, Pandita A, Koeppen H, French D, Polson AG, Offringa R, Whiting N, Ebens A, Dornan D. Sci Transl Med. 2011; 3 (74): 74ra22
• Current concepts and controversies in the management of early stage Hodgkin lymphoma. Maeda LS, Lee M, Advani RH. Leuk Lymphoma. 2011; 52 (6): 962-71
• Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus. Nguyen TT, Gubens M, Arber DA, Advani R, Juretzka M, Aziz N. Obstet Gynecol. 2011; 118 (2 Pt 2): 486-9
• MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S, Briones J, Natkunam Y, Sehn LH, Gascoyne RD, Tibshirani R, Lossos IS. Clin Cancer Res. 2011; 17 (12): 4125-35
• Optimal therapy of advanced Hodgkin lymphoma. Advani R, Hematology Am Soc Hematol Educ Program. 2011: 2011 310-6
• Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies. Galatin PS, Advani RH, Fisher GA, Francisco B, Julian T, Losa R, Sierra MI, Sikic BI. Invest New Drugs. 2011; 29 (5): 971-7
• Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Alizadeh AA, Gentles AJ, Alencar AJ, Liu CL, Kohrt HE, Houot R, Goldstein MJ, Zhao S, Natkunam Y, Advani RH, Gascoyne RD, Briones J, Tibshirani RJ, Myklebust JH, Plevritis SK, Lossos IS, Levy R. Blood. 2011; 118 (5): 1350-8
• Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience. Advani RH, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, Horning SJ. Int J Radiat Oncol Biol Phys. 2011; 81 (5): 1374-9
• Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ. Br J Haematol. 2010; 151 (2): 143-51
• In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. J Clin Oncol. 2010; 28 (28): 4324-32
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Horning SJ, Juweid ME, Schöder H, Wiseman G, McMillan A, Swinnen LJ, Advani R, Gascoyne R, Quon A. Blood. 2010; 115 (4): 775-7; quiz 918
• Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). Gratzinger D, Advani R, Zhao S, Talreja N, Tibshirani RJ, Shyam R, Horning S, Sehn LH, Farinha P, Briones J, Lossos IS, Gascoyne RD, Natkunam Y. Br J Haematol. 2010; 148 (2): 235-44
• Risk stratification in extranodal natural killer/T-cell lymphoma. Kohrt H, Lee M, Advani R. Expert Rev Anticancer Ther. 2010; 10 (9): 1395-405
• Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules. Advani RH, Hurwitz HI, Gordon MS, Ebbinghaus SW, Mendelson DS, Wakelee HA, Hoch U, Silverman JA, Havrilla NA, Berman CJ, Fox JA, Allen RS, Adelman DC. Clin Cancer Res. 2010; 16 (7): 2167-75
• Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease. Kohrt H, Johannsen A, Hoppe R, Horning SJ, Rosenberg SA, Advani R, Lee PP. Oncol Res. 2009; 18 (5-6): 287-92
• Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment. Kohrt H, Advani R. Leuk Lymphoma. 2009; 50 (11): 1773-84
• Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. J Clin Oncol. 2009; 27 (26): 4371-7
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH. Arch Dermatol. 2009; 145 (6): 667-74
• Targeting CD40 in Waldenström's macroglobulinemia. Lee M, Advani R. Clin Lymphoma Myeloma. 2009; 9 (1): 87-9
• The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Maeda LS, Advani RH. Curr Opin Oncol. 2009; 21 (5): 397-400
• Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development. Chen AI, Advani RH. J Natl Compr Canc Netw. 2008; 6 (4): 428-35
• Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Alizadeh AA, Advani RH. Clin Adv Hematol Oncol. 2008; 6 (12): 899-909
• Hodgkin disease/lymphoma. Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD. J Natl Compr Canc Netw. 2008; 6 (6): 594-622
• Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (6): 953-7
• Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Advani R, Horwitz S, Zelenetz A, Horning SJ. Leuk Lymphoma. 2007; 48 (3): 521-5
• Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. J Clin Oncol. 2007; 25 (25): 3902-7
• Non-Hodgkin lymphoma of the breast. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S. Cancer. 2007; 110 (1): 25-30
• Management of advanced stage Hodgkin lymphoma. Advani R, Ai WZ, Horning SJ. J Natl Compr Canc Netw. 2006; 4 (3): 241-7
• Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, Advani R, Warnke R, Kohler S, Hoppe RT, Kim YH. Arch Dermatol. 2006; 142 (5): 577-84
• Treatment of mantle cell lymphoma: current approach and future directions. Brody J, Advani R. Crit Rev Oncol Hematol. 2006; 58 (3): 257-65
• A Phase I Trial of Aprinocarsen (ISIS 3521/LY900003), an Antisense Inhibitor of Protein Kinase C-alpha Administered as a 24-hour Weekly Infusion Schedule in Patients with Advanced Cancer. Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, and Sikic BI.. Investigational New Drugs,. 2005 In Press
• A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. Advani R, Lum BL, Fisher GA, Halsey J, Geary RS, Holmlund JT, Kwoh TJ, Dorr FA, Sikic BI. Invest New Drugs. 2005; 23 (5): 467-77
• A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. Advani R, Lum BL, Fisher GA, Halsey J, Chin DL, Jacobs CD, Sikic BI. Ann Oncol. 2005; 16 (12): 1968-73
• Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM. J Clin Oncol. 2004; 22 (6): 1078-86
• Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. Advani R, Rosenberg SA, Horning SJ. J Clin Oncol. 2004; 22 (8): 1454-9
• Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI. Clin Cancer Res. 2003; 9 (14): 5187-94
• A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. Clin Cancer Res. 2001; 7 (5): 1221-9
• Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Advani R,, Saba HI, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Sikic BI, Davis E, Paietta E, Litchman M and Greenberg P.. Blood. 1999: 93 787-95